Cardiac and Renal Protective Effects of Irbesartan via Peroxisome Proliferator-Activated Receptor -Hepatocyte Growth Factor Pathway Independent of Angiotensin II Type 1a Receptor Blockade in Mouse Model of Salt-Sensitive Hypertension

Journal of the American Heart Association - United Kingdom
doi 10.1161/jaha.113.000103
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Cardiac Peroxisome-Proliferator-Activated Receptor Expression in Hypertension Co-Existing With Diabetes

Clinical Science
Medicine
2011English

Peroxisome Proliferator-Activated Receptor

English

Peroxisome Proliferator Activated Receptor

English

Peroxisome Proliferator-Activated Receptor Gamma Agonists in Renal Disease

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2006English

Troglitazone Attenuates Epidermal Growth Factor Receptor Signaling Independently of Peroxisome Proliferator-Activated Receptor in PC-3 Cells

Oncology Reports
MedicineCancer ResearchOncology
2010English

Angiotensin II Type 2 Receptor Blockade Partially Negates Antihypertrophic Effects of Type 1 Receptor Blockade on Pressure-Overload Rat Cardiac Hypertrophy.

Hypertension Research
Internal MedicineCardiovascular MedicinePhysiologyCardiology
2003English

Protective Effects of Peroxisome Proliferator-Activated Receptor Agonists on Human Podocytes: Proposed Mechanisms of Action

British Journal of Pharmacology
Pharmacology
2012English

Hypoxia Inhibits the Peroxisome Proliferator-Activated Receptor Α/ Retinoid X Receptor Gene Regulatory Pathway in Cardiac Myocytes

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2001English

AT1-receptor Blockade: Protective Effects of Irbesartan in Cardiomyocytes Under Hypoxic Stress

PLoS ONE
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy